Customer Service: (855) 848-6626 | 8:00 a.m - 4:30 p.m. PST | Save 35% on Ghost Dyes™

Recombinant Human FGFR2a (IIIc) Fc (Carrier-free)
  • Recombinant Human FGFR2a (IIIc) Fc (Carrier-free)

Recombinant Human FGFR2a (IIIc) Fc (Carrier-free)

Cat No. Size Price Quantity
21-7105-U010 10 µg $69.00
21-7105-U050 50 µg $169.00
21-7105-U100 100 µg $280.00
21-7105-U500 500 µg $859.00

Description

The Fibroblast Growth Factor Receptor (FGFR) family is made up of four known closely related receptor tyrosine kinases, FGFR1 through 4. For FGFR1 through 3, alternative splicing results in numerous variants. One common splicing event results in the extracellular domain having all 3 immunoglobulin-like domains (alpha isoform) or only the II and III Ig domains (beta isoform). Additional variation in the IgIII domain allows for expression as IIIb or IIIc, again due to alternative splicing. Ligand binding results in dimerization and autophosphorylation of specific tyrosine residues. Variants may exhibit different ligand binding properties. Depending on the isoform, FGFR2 binds FGF-acidic, FGF-basic and keratinocyte growth factor ligands with high affinity.
View More
The Fibroblast Growth Factor Receptor (FGFR) family is made up of four known closely related receptor tyrosine kinases, FGFR1 through 4. For FGFR1 through 3, alternative splicing results in numerous variants. One common splicing event results in the extracellular domain having all 3 immunoglobulin-like domains (alpha isoform) or only the II and III Ig domains (beta isoform). Additional variation in the IgIII domain allows for expression as IIIb or IIIc, again due to alternative splicing. Ligand binding results in dimerization and autophosphorylation of specific tyrosine residues. Variants may exhibit different ligand binding properties. Depending on the isoform, FGFR2 binds FGF-acidic, FGF-basic and keratinocyte growth factor ligands with high affinity.
Hide

Product Details

Name Recombinant Human FGFR2a (IIIc) Fc (Carrier-free)
Cat. No. 21-7105
Alternative Names Fibroblast Growth Factor Receptor 2 alpha, BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM
Amino Acid Sequence (Monomer) RPSFSLVEDT TLEPEEPPTK YQISQPEVYV AAPGESLEVR CLLKDAAVIS WTKDGVHLGP NNRTVLIGEY LQIKGATPRD SGLYACTASR TVDSETWYFM VNVTDAISSG DDEDDTDGAE DFVSENSNNK RAPYWTNTEK MEKRLHAVPA ANTVKFRCPA GGNPMPTMRW LKNGKEFKQE HRIGGYKVRN QHWSLIMESV VPSDKGNYTC VVENEYGSIN HTY
Authenticity Verified by N-terminal and Mass Spectrometry analyses (when applicable).
Bioactivity Assay#1: The expected ED50, determined by the dose-dependent stimulation of thymidine uptake by BaF3 cells expressing FGF receptors, is ≤ 0.5 ng/ml corresponding to a specific activity of ≥ 2 x 106 units/mg. Assay #2: The expected ED
Endotoxin Level Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg).
Molecular Mass Recombinant Human FGFR2a (IIIc) migrates between ≥ ≥ ≥ 100-110 kDa on SDS-PAGE gel under reducing conditions. It is a 65.6 kDa protein containing 589 amino acids.
Protein Content Verified by UV Spectroscopy and/or SDS-PAGE gel.
Purity (%) 95
Source CHO cells
Reactivity Human
Research Areas Angiogenesis & Cardiovascular, Cancer, Differentiation,? FGF Superfamily, Inflammation, Neurobiology, Stem Cells, Wound Healing
Reconstitution See Certificate of Analysis (COA) for lot specific reconstitution information.
Application Bioassay
Application Key:

FC = Flow Cytometry; FA = Functional Assays; ELISA = Enzyme-Linked Immunosorbent Assay; ICC = Immunocytochemistry; IF = Immunofluorescence Microscopy; IHC = Immunohistochemistry; IHC-F = Immunohistochemistry, Frozen Tissue; IHC-P = Immunohistochemistry, Paraffin-Embedded Tissue; IP = Immunoprecipitation; WB = Western Blot; EM = Electron Microscopy

*Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult the Materials and Methods section for additional details about the use of any product in these publications.